Reverse DCF
What growth does the market imply for SUNPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
13.2% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹1,659
Historical Growth
18.0%
FCF Yield
2.58%
Price / FCF
38.8x
Plain English
To justify today's price of $1658.90, SUNPHARMA.NS needs to grow its free cash flow at 13.2% per year for the next 10 years. That is 4.8% slower than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 6.6% | ₹989 | -40.4% |
| GDP rate | 10.0% | ₹1,286 | -22.5% |
| Implied | 13.2% | ₹1,656 | -0.2% |
| Historical | 18.0% | ₹2,401 | +44.7% |
At Historical Growth Rate
It would take 7 years for SUNPHARMA to organically grow into today's price assuming its historical FCF growth of 18.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.